IGSF22 Antibody
Novus Biologicals, part of Bio-Techne | Catalog # NBP3-17595
Key Product Details
Species Reactivity
Human
Applications
Immunocytochemistry/ Immunofluorescence
Label
Unconjugated
Antibody Source
Polyclonal Rabbit IgG
Concentration
Concentrations vary lot to lot. See vial label for concentration. If unlisted please contact technical services.
Product Specifications
Immunogen
This antibody was developed against Recombinant Protein corresponding to amino acids: VPKKDFEKVCMEYGFTDFRGLLRKLKEMKKKVEVEAIRILKPLEDKETKVDTTVVFDCIMELKDPNVKMIWIKGTEPLRIQYSLGKYDVKQMGTKY
Clonality
Polyclonal
Host
Rabbit
Isotype
IgG
Scientific Data Images for IGSF22 Antibody
Immunocytochemistry/ Immunofluorescence: IGSF22 Antibody [NBP3-17595]
Immunocytochemistry/Immunofluorescence: IGSF22 Antibody [NBP3-17595] - Staining of human cell line RH-30 shows localization to mitochondria.Applications for IGSF22 Antibody
Application
Recommended Usage
Immunocytochemistry/ Immunofluorescence
0.25-2 ug/ml
Application Notes
Immunocytochemistry/Immunofluorescence, PFA/Triton X-100 is recommended for fixation/permeabilization.
Formulation, Preparation, and Storage
Purification
Affinity purified
Formulation
PBS, pH 7.2, 40% glycerol
Preservative
0.02% Sodium Azide
Concentration
Concentrations vary lot to lot. See vial label for concentration. If unlisted please contact technical services.
Shipping
The product is shipped with polar packs. Upon receipt, store it immediately at the temperature recommended below.
Stability & Storage
Store at 4C short term. Aliquot and store at -20C long term. Avoid freeze-thaw cycles.
Background: IGSF22
Alternate Names
FLJ37794, IgSF22, immunoglobulin superfamily member 22, immunoglobulin superfamily, member 22
Gene Symbol
IGSF22
Additional IGSF22 Products
Product Documents for IGSF22 Antibody
Product Specific Notices for IGSF22 Antibody
This product is for research use only and is not approved for use in humans or in clinical diagnosis. Primary Antibodies are guaranteed for 1 year from date of receipt.
Loading...
Loading...
Loading...
Loading...